Related Experiment Videos
Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers
1Institut für Immunologie, Ludwig-Maximilians-Universität, München, Germany.
Abstract:
The initial promise of monoclonal antibodies as major therapeutic agents in human epithelial cancer has not been realized. Inaccessibility of cells in solid tumors due to factors such as the nature of the vascular endothelia and high pressure in the tumor are primarily responsible for the failure of antibody therapy. Although new strategies employing recombinant antibodies and immunoglobulins designed to actively engage the immune system may prove beneficial, micrometastatic tumor cells (at the stage of minimal residual disease) are likely to be the only suitable targets for antibody therapy. The diagnostic approaches to identify and characterize these cells and their use for prognosis and monitoring adjuvant immunotherapy is discussed.
Insights
Monoclonal antibody therapy for epithelial cancer faces challenges due to tumor inaccessibility. Future strategies may target micrometastatic cells for effective cancer treatment and monitoring.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) show limited efficacy in treating human epithelial cancers.
- Solid tumor characteristics, including vascular endothelium and high interstitial pressure, impede mAb delivery and effectiveness.
- Current therapeutic strategies have not fully realized the potential of mAbs in cancer treatment.
Purpose of the Study:
- To analyze the limitations of current antibody therapy in epithelial cancers.
- To explore novel strategies for improving antibody-based cancer treatments.
- To discuss diagnostic approaches for identifying and monitoring micrometastatic cancer cells.
Main Methods:
- Review of existing literature on antibody therapy in solid tumors.
- Analysis of factors limiting drug delivery and efficacy within tumors.
- Discussion of emerging recombinant antibody and immunotherapy strategies.
- Exploration of diagnostic methods for micrometastatic cell detection.
Main Results:
- Inaccessibility of solid tumor cells is a primary barrier to effective mAb therapy.
- Recombinant antibodies and immune-engaging immunoglobulins offer potential improvements.
- Micrometastatic tumor cells represent a promising target for antibody-based interventions.
- Diagnostic tools are crucial for identifying suitable targets and monitoring treatment response.
Conclusions:
- The therapeutic promise of mAbs in epithelial cancers remains largely unmet due to physical barriers.
- Targeting micrometastatic disease with advanced antibody therapies and diagnostics is a key future direction.
- Effective prognosis and monitoring of adjuvant immunotherapy rely on accurate characterization of minimal residual disease.